North Star Asset Management Inc. Increases Stock Position in Novo Nordisk A/S $NVO

North Star Asset Management Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 19.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,464 shares of the company’s stock after buying an additional 6,752 shares during the period. North Star Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,862,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Jennison Associates LLC grew its holdings in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the period. Kingstone Capital Partners Texas LLC lifted its position in Novo Nordisk A/S by 301,443.6% during the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Sustainable Growth Advisers LP lifted its position in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after buying an additional 649,390 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Novo Nordisk A/S by 11.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock worth $395,291,000 after buying an additional 576,900 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter worth $370,272,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 5.5%

Shares of Novo Nordisk A/S stock opened at $44.99 on Tuesday. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $112.52. The company has a market capitalization of $200.88 billion, a PE ratio of 12.36, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The business has a 50-day moving average of $53.71 and a 200-day moving average of $60.14.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. TD Cowen decreased their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 19th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a research note on Wednesday, August 13th. Finally, Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $57.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.